SEARCH

SEARCH BY CITATION

References

  • 1
    Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacy Ther 54: 205218.September 0000
  • 2
    Schroeder TJ, Hariharan S, First MR. Relationship between cyclosporine bioavailability and clinical outcome in renal transplant recipients. Transplant Proc 1994; 26: 27872790.
  • 3
    Kahan BD, Dunn J, Fitts C et al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation 1995; 59: 505511.
  • 4
    Savoldi S, Maiorca R, Chiappini R et al. Trough cyclosporine concentration variability. Transplant Proc 1998; 30: 16421644.
  • 5
    Johnston A, Sketris I, Marsden JT et al. A limited sampling strategy for the measurement of cyclosporin AUC. Transplant Proc 1990; 22: 13451346.
  • 6
    Grevel J, Kahan B. Abbreviated kinetic profiles in area under the curve monitoring of cyclosporine therapy. Clin Chem 1991; 37: 1905.
  • 7
    Serino F, Citterio F, Pozzetto U, Grevel J, Castagneto M. Abbreviated three-point kinetic profile in the 12-hour area under the curve for pharmacokinetic monitoring of cyclosporine. Transplant Proc 1994; 26: 2807.
  • 8
    Johnson A, Kovarik JM, Mueller EA, Holt DW. Predicting patients' exposure to cyclosporin. Transplant Int 1996; 9 (Suppl. 1): S305S307.
  • 9
    Holt DW, Mueller EA, Kovarik JM, Van Bree JB, Kutz K. The pharmacokinetics of Sandimmune Neoral: a new formulation of cyclosporine. Transplant Proc 1994; 26: 2935.
  • 10
    Barone G, Bunke CM, Choc MG et al. Safety and tolerability of Neoral vs cyclosporine in a randomized, double-blind comparison in primary renal allograft recipients. Transplantation 1996; 61: 968.
  • 11
    Keown P, Landsberg D, Halloran P et al. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Transplantation 1996; 62: 1744.
  • 12
    Amante AJ, Kahan BD. Abbreviated AUC strategy for monitoring cyclosporine microemulsion therapy in the immediate posttransplant period. Transplant Proc 1996; 28: 21622163.
  • 13
    Gaspari F, Anedda MF, Signorini O, Remuzzi G, Perico N. Prediction of cyclosporine area under the curve using a three point sampling strategy after Neoral® administration. J Am Soc Nephrol 1997; 8: 647.
  • 14
    Keown P. Experience with use of sparse-sample-derived AUCs for management of Neoral. Focus on Medicine 1998; 13: 1114.
  • 15
    Mahalati K, Belitsky P, Sketris I et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve. Transplantation 1999; 68: 5562.
  • 16
    Belitsky P, Levy GA, Johnston A. Neoral absorption profiling: an evolution in effectiveness. Transplant Proc 2000; 32 (Suppl. 3A): 45S52S.
  • 17
    Mahalati K, Belitsky P, West K et al. Approaching the therapeutic window for cyclosporine in kidney transplantation: a prospective study. J Am Soc Nephrol 2001; 12: 828833.
  • 18
    Johnston A, David OJ, Cooney GF. Pharmacokinetic validation of Neoral absorption profiling. Transplant Proc 2000; 32 (Suppl. 3A): 53S56S.
  • 19
    Grant D, Kneteman N, Tchervenkov J et al. Peak cyclosporin levels (Cmax) correlate with freedom from liver graft rejection. Transplantation 1999; 67: 11331137.
  • 20
    Cantarovich M, Besner J-G, Barkun JS et al. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant 1998; 12: 243249.
  • 21
    Levy G. Two-hour cyclosporin concentration (C2) as a monitoring tool for Neoral. Focus on Medicine 1998; 13: 1922.
  • 22
    Mahalati K, Belitsky P, Lawen JG, Kiberd B. Is 3-hour cyclosporine level superior to trough level in early post renal transplant period? J Urol 2000; 163: 3741.
  • 23
    Metz CE. Basic principles of ROC analysis. Semin Nuclear Medical 1978; 8: 283298.
  • 24
    Et Al.Salomon DR, Stablein DM, Van Buren DH, West JC. Long-term efficacy and safety of cyclosporine in renal-transplant recipients. N Engl J Med 1994; 331: 358363.
  • 25
    Halloran P. Calcineurin inhibition – relationship to cyclosporin blood concentration. Focus on Medicine 1998; 13: 1518.